US CLEARS FIRST ‘LIVING DRUG’ FOR TOUGH CHILDHOOD LEUKEMIA
Sep 01, 2017
3 minutes
Opening a new era in cancer care, the Food and Drug Administration on Wednesday approved the first treatment that genetically engineers patients’ own blood cells into an army of assassins to seek and destroy childhood leukemia.
The CAR-T cell treatment developed by Novartis and the University of Pennsylvania is the first type of gene therapy to hit the U.S. market - and one in a powerful but expensive wave of
You’re reading a preview, subscribe to read more.
Start your free 30 days